Maryland - SciVal Experts v3.6

312 Publications

This is a list of publications by this researcher, listed chronologically starting with the most recent first. New publications appear in this list weekly. The source of publications for this application is PubMed, so only PubMed publications are included.

Select All |

Export to Endnote

1.
2012

Patricia M Lorusso; Martin J Edelman; Susan L Bever; Karen M Forman; Maryjo Pilat; Mary F Quinn; Jing Li; Elisabeth I Heath; Lisa M Malburg; Patrick J Klein; et al.

Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(32):4011-6.
2.
2012

Edward A Sausville

Promises from trametinib in RAF active tumors.
The New England journal of medicine 2012;367(2):171-2.
3.
2011

Shiven B Patel; Ivana Gojo; Michael L Tidwell; Edward A Sausville; Maria R Baer

Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.
Leukemia & lymphoma 2011;52(7):1211-4.
4.
2011

Christopher P Leamon; Joseph A Reddy; Patrick J Klein; Iontcho R Vlahov; Ryan Dorton; Alicia Bloomfield; Melissa Nelson; Elaine Westrick; Nikki Parker; Kristen Bruna; et al.

Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications.
The Journal of pharmacology and experimental therapeutics 2011;336(2):336-43.
5.
2010

Ulka N Vaishampayan; Angelika M Burger; Edward A Sausville; Lance K Heilbrun; Jing Li; M Naomi Horiba; Merrill J Egorin; Percy Ivy; Simon Pacey; Patricia M Lorusso

Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(14):3795-804.
6.
2010

Shivaani Kummar; Martin E Gutierrez; Erin R Gardner; William D Figg; Giovanni Melillo; Janet Dancey; Edward A Sausville; Barbara A Conley; Anthony J Murgo; James H Doroshow

A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
Cancer chemotherapy and pharmacology 2010;65(2):383-9.
7.
2009

Jing Li; Edward A Sausville; Patrick J Klein; David Morgenstern; Christopher P Leamon; Richard A Messmann; Patricia LoRusso

Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients.
Journal of clinical pharmacology 2009;49(12):1467-76.
8.
2009

Mark P Borgman; Omer Aras; Sandra Geyser-Stoops; Edward A Sausville; Hamidreza Ghandehari

Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.
Molecular pharmaceutics 2009;6(6):1836-47.
9.
2009

Mark P Borgman; Abhijit Ray; Rohit B Kolhatkar; Edward A Sausville; Angelika M Burger; Hamidreza Ghandehari

Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.
Pharmaceutical research 2009;26(6):1407-18.
10.
2009

Edward A Sausville

Mitochondrial function as an emerging 'target of interest' for cancer treatment.
Current opinion in investigational drugs (London, England : 2000) 2009;10(6):523-5.
11.
2009

Ken Shiozawa; Takeo Nakanishi; Ming Tan; Hong-Bin Fang; Wen-chyi Wang; Martin J Edelman; David Carlton; Ivana Gojo; Edward A Sausville; Douglas D Ross

Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(5):1698-707.
12.
2009

Merry Y Zhao; Aaron Auerbach; Anisha M D'Costa; Aaron P Rapoport; Angelika M Burger; Edward A Sausville; Sanford A Stass; Feng Jiang; Amy M Sands; Nadine Aguilera; et al.

Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(5):1708-20.
13.
2008

Hong-Bin Fang; Douglas D Ross; Edward Sausville; Ming Tan

Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses.
Statistics in medicine 2008;27(16):3071-83.
14.
2007

Scott E Strome; Edward A Sausville; Dean Mann

A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects.
The oncologist 2007;12(9):1084-95.
15.
2007

Ivana Gojo; Anchalee Jiemjit; Jane B Trepel; Alex Sparreboom; William D Figg; Sandra Rollins; Michael L Tidwell; Jacqueline Greer; Eun Joo Chung; Min-Jung Lee; et al.

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
Blood 2007;109(7):2781-90.
16.
2007

Son B Le; M Katie Hailer; Sarah Buhrow; Qi Wang; Karen Flatten; Peter Pediaditakis; Keith C Bible; Lionel D Lewis; Edward A Sausville; Yuan-Ping Pang; et al.

Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity.
The Journal of biological chemistry 2007;282(12):8860-72.
17.
2006

Indranil Mukhopadhyay; Edward A Sausville; James H Doroshow; Krishnendu K Roy

Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways.
The Journal of biological chemistry 2006;281(49):37330-44.
18.
2006

Milin R Acharya; Judith E Karp; Edward A Sausville; Kyunghwa Hwang; Qin Ryan; Ivana Gojo; Jurgen Venitz; William D Figg; Alex Sparreboom

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
Investigational new drugs 2006;24(5):367-75.
19.
2006

Edward A Sausville

Respecting cancer drug transportability: a basis for successful lead selection.
Journal of the National Cancer Institute 2006;98(16):1098-9.
20.
2006

Akrit Sodhi; Risa Chaisuparat; Jiadi Hu; Amanda K Ramsdell; Brendan D Manning; Edward A Sausville; Earl T Sawai; Alfredo Molinolo; J Silvio Gutkind; Silvia Montaner

The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.
Cancer cell 2006;10(2):133-43.
21.
2006

Eileen Brantley; Smitha Antony; Glenda Kohlhagen; Linghua Meng; Keli Agama; Sherman F Stinson; Edward A Sausville; Yves Pommier

Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells.
Cancer chemotherapy and pharmacology 2006;58(1):62-72.
22.
2006

Edward A Sausville; Angelika M Burger

Contributions of human tumor xenografts to anticancer drug development.
Cancer research 2006;66(7):3351-4, discussion 3354.
23.
2006

Joya Chandra; Jeannette Tracy; David Loegering; Karen Flatten; Srdan Verstovsek; Miloslav Beran; Mercedes Gorre; Zeev Estrov; Nicholas Donato; Moshe Talpaz; et al.

Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
Blood 2006;107(6):2501-6.
24.
2006

Anders Wallqvist; John Connelly; Edward A Sausville; David G Covell; Anne Monks

Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines.
Molecular pharmacology 2006;69(3):737-48.
25.
2006

Ashraf Badros; Dianna Weikel; Andrew Salama; Olga Goloubeva; Abraham Schneider; Aaron Rapoport; Robert Fenton; Natalie Gahres; Edward Sausville; Robert Ord; et al.

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):945-52.
26.
2006

Milin R Acharya; Alex Sparreboom; Edward A Sausville; Barbara A Conley; James H Doroshow; Jurgen Venitz; William D Figg

Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
Cancer chemotherapy and pharmacology 2006;57(3):275-81.
27.
2006

Mikhail G Kolonin; Laura Bover; Jessica Sun; Amado J Zurita; Kim-Anh Do; Johanna Lahdenranta; Marina Cardó-Vila; Ricardo J Giordano; Diana E Jaalouk; Michael G Ozawa; et al.

Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries.
Cancer research 2006;66(1):34-40.
28.
2006

S B Le; E L Holmuhamedov; V L Narayanan; E A Sausville; S H Kaufmann

Adaphostin and other anticancer drugs quench the fluorescence of mitochondrial potential probes.
Cell death and differentiation 2006;13(1):151-9.
29.
2005

Elizabeth R Glaze; Amy L Lambert; Adaline C Smith; John G Page; William D Johnson; David L McCormick; Alan P Brown; Barry S Levine; Joseph M Covey; Merrill J Egorin; et al.

Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
Cancer chemotherapy and pharmacology 2005;56(6):637-47.
30.
2005

Carter Van Waes; Angela A Chang; Peter F Lebowitz; Colleen H Druzgal; Zhong Chen; Yusri A Elsayed; John B Sunwoo; Susan F Rudy; John C Morris; James B Mitchell; et al.

Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
International journal of radiation oncology, biology, physics 2005;63(5):1400-12.
31.
2005

Panomwat Amornphimoltham; Vyomesh Patel; Akrit Sodhi; Nikolaos G Nikitakis; John J Sauk; Edward A Sausville; Alfredo A Molinolo; J Silvio Gutkind

Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Cancer research 2005;65(21):9953-61.
32.
2005

Shannon Decker; Edward A Sausville

Preclinical modeling of combination treatments: fantasy or requirement?
Annals of the New York Academy of Sciences 2005;1059():61-9.
33.
2005

Yongkui Jing; Nella Hellinger; Lijuan Xia; Anne Monks; Edward A Sausville; Arthur Zelent; Samuel Waxman

Benzodithiophenes induce differentiation and apoptosis in human leukemia cells.
Cancer research 2005;65(17):7847-55.
34.
2005

Curtis Hose; Gurmeet Kaur; Edward A Sausville; Anne Monks

Transcriptional profiling identifies altered intracellular labile iron homeostasis as a contributing factor to the toxicity of adaphostin: decreased vascular endothelial growth factor secretion is independent of hypoxia-inducible factor-1 regulation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6370-81.
35.
2005

Yuehai Shen; Qian Xie; Monica Norberg; Edward Sausville; George Vande Woude; David Wenkert

Geldanamycin derivative inhibition of HGF/SF-mediated Met tyrosine kinase receptor-dependent urokinase-plasminogen activation.
Bioorganic & medicinal chemistry 2005;13(16):4960-71.
36.
2005

Melinda Hollingshead; Michael Alley; Angelika M Burger; Suzanne Borgel; Christine Pacula-Cox; Heinz-Herbert Fiebig; Edward A Sausville

In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative.
Cancer chemotherapy and pharmacology 2005;56(2):115-25.
37.
2005

Victoria Smith; Edward A Sausville; Richard F Camalier; Heinz-Herbert Fiebig; Angelika M Burger

Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Cancer chemotherapy and pharmacology 2005;56(2):126-37.
38.
2005

Tamer E Fandy; Sharmila Shankar; Douglas D Ross; Edward Sausville; Rakesh K Srivastava

Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma.
Neoplasia (New York, N.Y.) 2005;7(7):646-57.
39.
2005

Ling-hua Meng; Glenda Kohlhagen; Zhi-yong Liao; Smitha Antony; Edward Sausville; Yves Pommier

DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells.
Cancer research 2005;65(12):5337-43.
40.
2005

Qin C Ryan; Donna Headlee; Milin Acharya; Alex Sparreboom; Jane B Trepel; Joseph Ye; William D Figg; Kyunghwa Hwang; Eun Joo Chung; Anthony Murgo; et al.

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3912-22.
41.
2005

Edward A Sausville; Michael A Carducci

Making bad cells go good: the promise of epigenetic therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3875-6.
42.
2005

Qian Xie; Chong-Feng Gao; Nariyoshi Shinomiya; Edward Sausville; Rick Hay; Margaret Gustafson; Yuehai Shen; David Wenkert; George F Vande Woude

Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.
Oncogene 2005;24(23):3697-707.
43.
2005

Connor F McGrath; Nagarajan Pattabiraman; Glen E Kellogg; Thomas Lemcke; Conrad Kunick; Edward A Sausville; Daniel W Zaharevitz; Rick Gussio

Homology model of the CDK1/cyclin B complex.
Journal of biomolecular structure & dynamics 2005;22(5):493-502.
44.
2005

Gabriela Tudor; Mike Alley; Christopher M Nelson; Ruili Huang; David G Covell; Peter Gutierrez; Edward A Sausville

Cytotoxicity of RH1: NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction.
Anti-cancer drugs 2005;16(4):381-91.
45.
2005

Eiichi Fuse; Takashi Kuwabara; Alex Sparreboom; Edward A Sausville; William D Figg

Review of UCN-01 development: a lesson in the importance of clinical pharmacology.
Journal of clinical pharmacology 2005;45(4):394-403.
46.
2005

Edward A Sausville

Indifferently pursued or unowned drugs: who should lead where companies do not tread?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(9):1796-8.
47.
2005

Gurmeet Kaur; Ven L Narayanan; Prabhakar A Risbood; Melinda G Hollingshead; Sherman F Stinson; Ravi K Varma; Edward A Sausville

Synthesis, structure-activity relationship, and p210(bcr-abl) protein tyrosine kinase activity of novel AG 957 analogs.
Bioorganic & medicinal chemistry 2005;13(5):1749-61.
48.
2005

Tait D Shanafelt; Yean K Lee; Nancy D Bone; Ann K Strege; Ven L Narayanan; Edward A Sausville; Susan M Geyer; Scott H Kaufmann; Neil E Kay

Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine.
Blood 2005;105(5):2099-106.
49.
2005

Eileen Brantley; Vyomesh Patel; Sherman F Stinson; Valentina Trapani; Curtis D Hose; Henry P Ciolino; Grace C Yeh; J Silvio Gutkind; Edward A Sausville; Andrea I Loaiza-Pérez

The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells.
Anti-cancer drugs 2005;16(2):137-43.
50.
2005

Pascale Moreau; Susan Holbeck; Michelle Prudhomme; Edward A Sausville

Cytotoxicities of three rebeccamycin derivatives in the National Cancer Institute screening of 60 human tumor cell lines.
Anti-cancer drugs 2005;16(2):145-50.
51.
2005

Mandar R Bhonde; Marie-Luise Hanski; Roberta Magrini; Dhatchana Moorthy; Antje Müller; Edward A Sausville; Kimitoshi Kohno; Peter Wiegand; Peter T Daniel; Martin Zeitz; et al.

The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein.
Oncogene 2005;24(1):148-56.
52.
2005

Edward A Sausville

Cell cycle regulatory kinase modulators: interim progress and issues.
Current topics in medicinal chemistry 2005;5(12):1109-17.
53.
2005

Eun Joo Chung; Sunmin Lee; Edward A Sausville; Qin Ryan; Judith E Karp; Ivana Gojo; William G Telford; Min-Jung Lee; Hye Sik Kong; Jane B Trepel

Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry.
Annals of clinical and laboratory science 2005;35(4):397-406.
54.
2004

Eileen Brantley; Valentina Trapani; Michael C Alley; Curtis D Hose; Tracey D Bradshaw; Malcolm F G Stevens; Edward A Sausville; Sherman F Stinson

Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(12):1392-401.
55.
2004

Kunwar Shailubhai; Surendra Dheer; Donald Picker; Gurmeet Kaur; Edward A Sausville; Gary S Jacob

Atiprimod is an inhibitor of cancer cell proliferation and angiogenesis.
Journal of experimental therapeutics & oncology 2004;4(4):267-79.
56.
2004

Miriam S Gitler; Edward A Sausville; Melinda Hollingshead; Robert Shoemaker

In vivo models for experimental therapeutics relevant to human cancer.
Cancer research 2004;64(22):8478-80.
57.
2004

E A Sausville

Target selection issues in drug discovery and development.
Journal of chemotherapy (Florence, Italy) 2004;16 Suppl 4():16-8.
58.
2004

E A Sausville

Geldanamycin analogs.
Journal of chemotherapy (Florence, Italy) 2004;16 Suppl 4():68-9.
59.
2004

Sudhir B Kondapaka; Maryjane Zarnowski; Dena R Yver; Edward A Sausville; Samuel W Cushman

7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(21):7192-8.
60.
2004

Edward A Sausville; Susan L Holbeck

Transcription profiling of gene expression in drug discovery and development: the NCI experience.
European journal of cancer (Oxford, England : 1990) 2004;40(17):2544-9.
61.
2004

Phyllis A Svingen; David Loegering; Joe Rodriquez; Xue Wei Meng; Peter W Mesner; Susan Holbeck; Anne Monks; Stan Krajewski; Dominic A Scudiero; Edward A Sausville; et al.

Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(20):6807-20.
62.
2004

Alex Sparreboom; Huachen Chen; Milin R Acharya; Adrian M Senderowicz; Richard A Messmann; Takashi Kuwabara; David J Venzon; Anthony J Murgo; Donna Headlee; Edward A Sausville; et al.

Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(20):6840-6.
63.
2004

John A Hartley; Victoria J Spanswick; Natalie Brooks; Peter H Clingen; Peter J McHugh; Daniel Hochhauser; R Barbara Pedley; Lloyd R Kelland; Michael C Alley; Robert Schultz; et al.

SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Cancer research 2004;64(18):6693-9.
64.
2004

Michael C Alley; Melinda G Hollingshead; Christine M Pacula-Cox; William R Waud; John A Hartley; Philip W Howard; Stephen J Gregson; David E Thurston; Edward A Sausville

SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
Cancer research 2004;64(18):6700-6.
65.
2004

Edward A Sausville

Optimizing target selection and development strategy in cancer treatment: the next wave.
Current medicinal chemistry. Anti-cancer agents 2004;4(5):445-7.
66.
2004

Edward A Sausville

Versipelostatin: unfolding an unsweetened death.
Journal of the National Cancer Institute 2004;96(17):1266-7.
67.
2004

Girija P Dasmahapatra; Parijat Didolkar; Michael C Alley; Somiranjan Ghosh; Edward A Sausville; Krishnendu K Roy

In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5242-52.
68.
2004

Gurmeet Kaur; Dorina Belotti; Angelika M Burger; Kirsten Fisher-Nielson; Patrizia Borsotti; Elena Riccardi; Jagada Thillainathan; Melinda Hollingshead; Edward A Sausville; Raffaella Giavazzi

Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4813-21.
69.
2004

Brian K Adams; Eva M Ferstl; Matthew C Davis; Marike Herold; Serdar Kurtkaya; Richard F Camalier; Melinda G Hollingshead; Gurmeet Kaur; Edward A Sausville; Frederick R Rickles; et al.

Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents.
Bioorganic & medicinal chemistry 2004;12(14):3871-83.
70.
2004

Panomwat Amornphimoltham; Virote Sriuranpong; Vyomesh Patel; Fernando Benavides; Claudio J Conti; John Sauk; Edward A Sausville; Alfredo A Molinolo; J Silvio Gutkind

Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4029-37.
71.
2004

Andrea I Loaiza-Pérez; Susan Kenney; Jamie Boswell; Melinda Hollingshead; Michael C Alley; Curtis Hose; Henry P Ciolino; Grace C Yeh; Jane B Trepel; David T Vistica; et al.

Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells.
Molecular cancer therapeutics 2004;3(6):715-25.
72.
2004

Kyunghwa Hwang; Milin R Acharya; Edward A Sausville; Suoping Zhai; Eunhee W Woo; Jürgen Venitz; William D Figg; Alex Sparreboom

Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;804(2):289-94.
73.
2004

Edward A Sausville

Genes in the service of therapeutic index: progress for virus-directed enzyme prodrug therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(9):1535-7.
74.
2004

Akrit Sodhi; Silvia Montaner; Vyomesh Patel; José Javier Gómez-Román; Yi Li; Edward A Sausville; Earl T Sawai; J Silvio Gutkind

Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(14):4821-6.
75.
2004

Angelika M Burger; Heinz-Herbert Fiebig; Sherman F Stinson; Edward A Sausville

17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
Anti-cancer drugs 2004;15(4):377-87.
76.
2004

S Decker; M Hollingshead; C A Bonomi; J P Carter; E A Sausville

The hollow fibre model in cancer drug screening: the NCI experience.
European journal of cancer (Oxford, England : 1990) 2004;40(6):821-6.
77.
2004

M G Hollingshead; C A Bonomi; S D Borgel; J P Carter; R Shoemaker; G Melillo; E A Sausville

A potential role for imaging technology in anticancer efficacy evaluations.
European journal of cancer (Oxford, England : 1990) 2004;40(6):890-8.
78.
2004

A I Loaiza-Pérez; S Kenney; J Boswell; M Hollingshead; C Hose; W M Linehan; R Worrell; L Rubinstein; E A Sausville; D T Vistica

Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.
The Journal of urology 2004;171(4):1688-97.
79.
2004

Edward A Sausville

Aurora kinases dawn as cancer drug targets.
Nature medicine 2004;10(3):234-5.
80.
2004

Chunrong Yu; Mohamed Rahmani; Jorge Almenara; Edward A Sausville; Paul Dent; Steven Grant

Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process.
Oncogene 2004;23(7):1364-76.
81.
2004

Maria Rosa Bani; Maria Ines Nicoletti; Nawal W Alkharouf; Carmen Ghilardi; David Petersen; Eugenio Erba; Edward A Sausville; Edison T Liu; Raffaella Giavazzi

Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts.
Molecular cancer therapeutics 2004;3(2):111-21.
82.
2004

Edward Sausville

Protein chaperones as anticancer therapy targets.
Clinical advances in hematology & oncology : H&O 2004;2(2):92-3.
83.
2004

Rekha G Panchal; Ann R Hermone; Tam Luong Nguyen; Thiang Yian Wong; Robert Schwarzenbacher; James Schmidt; Douglas Lane; Connor McGrath; Benjamin E Turk; James Burnett; et al.

Identification of small molecule inhibitors of anthrax lethal factor.
Nature structural & molecular biology 2004;11(1):67-72.
84.
2004

Aaron D Schimmer; Kate Welsh; Clemencia Pinilla; Zhiliang Wang; Maryla Krajewska; Marie-Josee Bonneau; Irene M Pedersen; Shinichi Kitada; Fiona L Scott; Beatrice Bailly-Maitre; et al.

Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity.
Cancer cell 2004;5(1):25-35.
85.
2003

Joya Chandra; Jennifer Hackbarth; Son Le; David Loegering; Nancy Bone; Laura M Bruzek; Ven L Narayanan; Alex A Adjei; Neil E Kay; Ayalew Tefferi; et al.

Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.
Blood 2003;102(13):4512-9.
86.
2003

Curtis D Hose; Melinda Hollingshead; Edward A Sausville; Anne Monks

Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity.
Molecular cancer therapeutics 2003;2(12):1265-72.
87.
2003

Anders Wallqvist; Alfred A Rabow; Robert H Shoemaker; Edward A Sausville; David G Covell

Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data.
Bioinformatics (Oxford, England) 2003;19(17):2212-24.
88.
2003

Robert M Sharkey; Edward A Sausville; David M Goldenberg

Meeting report on the Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates.
Cancer research 2003;63(22):8069-71.
89.
2003

Sudhir B Kondapaka; Sheo S Singh; Girija P Dasmahapatra; Edward A Sausville; Krishnendu K Roy

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
Molecular cancer therapeutics 2003;2(11):1093-103.
90.
2003

James C Burnett; James J Schmidt; Robert G Stafford; Rekha G Panchal; Tam L Nguyen; Ann R Hermone; Jonathan L Vennerstrom; Connor F McGrath; Douglas J Lane; Edward A Sausville; et al.

Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity.
Biochemical and biophysical research communications 2003;310(1):84-93.
91.
2003

Michelle A Rudek; Kenneth S Bauer; Richard M Lush; Sherman F Stinson; Adrian M Senderowicz; Donna J Headlee; Susan G Arbuck; Michael C Cox; Anthony J Murgo; Edward A Sausville; et al.

Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
The Annals of pharmacotherapy 2003;37(10):1369-74.
92.
2003

Edward A Sausville; Joseph E Tomaszewski; Percy Ivy

Clinical development of 17-allylamino, 17-demethoxygeldanamycin.
Current cancer drug targets 2003;3(5):377-83.
93.
2003

Ioannis A Avramis; Walter E Laug; Edward A Sausville; Vassilios I Avramis

Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Cancer chemotherapy and pharmacology 2003;52(4):307-18.
94.
2003

Constance J Glover; Karen Hite; Renee DeLosh; Dominic A Scudiero; Matthew J Fivash; Lindsey R Smith; Robert J Fisher; Jia Wei Wu; Yigong Shi; Rachael A Kipp; et al.

A high-throughput screen for identification of molecular mimics of Smac/DIABLO utilizing a fluorescence polarization assay.
Analytical biochemistry 2003;320(2):157-69.
95.
2003

Satoshi Nishizuka; Sing-Tsung Chen; Fuad G Gwadry; Jes Alexander; Sylvia M Major; Uwe Scherf; William C Reinhold; Mark Waltham; Lu Charboneau; Lynn Young; et al.

Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling.
Cancer research 2003;63(17):5243-50.
96.
2003

Wentao Jia; Chunrong Yu; Mohamed Rahmani; Geoffrey Krystal; Edward A Sausville; Paul Dent; Steven Grant

Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.
Blood 2003;102(5):1824-32.
97.
2003

Miriam S Gitler; Anne Monks; Edward A Sausville

Preclinical models for defining efficacy of drug combinations: mapping the road to the clinic.
Molecular cancer therapeutics 2003;2(9):929-32.
98.
2003

Susanna M Rybak; Elena Sanovich; Melinda G Hollingshead; Suzanne D Borgel; Dianne L Newton; Giovanni Melillo; Dehe Kong; Gurmeet Kaur; Edward A Sausville

"Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies.
Cancer research 2003;63(11):2812-9.
99.
2003

Edward A Sausville

Imatinib for chronic myelogenous leukaemia: a 9 or 24 carat gold standard?
Lancet 2003;361(9367):1400-1.
100.
2003

Edward A Sausville

Is another bcr-abl inhibitor needed for chronic myelogenous leukemia?
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1233-4.
101.
2003

Gabriela Tudor; Peter Gutierrez; Angelica Aguilera-Gutierrez; Edward A Sausville

Cytotoxicity and apoptosis of benzoquinones: redox cycling, cytochrome c release, and BAD protein expression.
Biochemical pharmacology 2003;65(7):1061-75.
102.
2003

Janet Dancey; Edward A Sausville

Issues and progress with protein kinase inhibitors for cancer treatment.
Nature reviews. Drug discovery 2003;2(4):296-313.
103.
2003

Anne Monks; Erik Harris; Curtis Hose; John Connelly; Edward A Sausville

Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole.
Molecular pharmacology 2003;63(3):766-72.
104.
2003

V Trapani; V Patel; C-O Leong; H P Ciolino; G C Yeh; C Hose; J B Trepel; M F G Stevens; E A Sausville; A I Loaiza-Pérez

DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.
British journal of cancer 2003;88(4):599-605.
105.
2003

Suoping Zhai; Edward A Sausville; Adrian M Senderowicz; Yuichi Ando; Donna Headlee; Richard A Messmann; Susan Arbuck; Anthony J Murgo; Giovanni Melillo; Eiichi Fuse; et al.

Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.
Anti-cancer drugs 2003;14(2):125-35.
106.
2003

Richard A Messmann; Claudio Dansky Ullmann; Tyler Lahusen; Audrey Kalehua; Jason Wasfy; Giovanni Melillo; Ivan Ding; Donna Headlee; William D Figg; Edward A Sausville; et al.

Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):562-70.
107.
2003

L Panasci; S F Stinson; D Melnychuk; V Sandor; W H Miller; G Batist; F Patenaude; N Bangash; L Panarello; M Alaoui-Jamali; et al.

SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):232-40.
108.
2003

Edward A Sausville; Yusri Elsayed; Manish Monga; George Kim

Signal transduction--directed cancer treatments.
Annual review of pharmacology and toxicology 2003;43():199-231.
109.
2003

Edward A Sausville

Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies.
Current medicinal chemistry. Anti-cancer agents 2003;3(1):47-56.
110.
2003

Bin-Bing S Zhou; Edward A Sausville

Drug discovery targeting Chk1 and Chk2 kinases.
Progress in cell cycle research 2003;5():413-21.
111.
2003

Edward Sausville; Jaap Verweij

Highlights from the EORTC-NCI-AACR 2002 meeting: molecular targets and cancer therapeutics.
Clinical advances in hematology & oncology : H&O 2003;1(1):22-3.
112.
2002

Ioannis A Avramis; Garyfallia Christodoulopoulos; Atsushi Suzuki; Walter E Laug; Ignacio Gonzalez-Gomez; George McNamara; Edward A Sausville; Vassilios I Avramis

In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.
Cancer chemotherapy and pharmacology 2002;50(6):479-89.
113.
2002

David J Newman; Gordon M Cragg; Susan Holbeck; Edward A Sausville

Natural products and derivatives as leads to cell cycle pathway targets in cancer chemotherapy.
Current cancer drug targets 2002;2(4):279-308.
114.
2002

Vyomesh Patel; Tyler Lahusen; Chidchanok Leethanakul; Tadashi Igishi; Marcus Kremer; Leticia Quintanilla-Martinez; John F Ensley; Edward A Sausville; J Silvio Gutkind; Adrian M Senderowicz

Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(11):3549-60.
115.
2002

Antoinette R Tan; Donna Headlee; Richard Messmann; Edward A Sausville; Susan G Arbuck; Anthony J Murgo; Giovanni Melillo; Suoping Zhai; William D Figg; Sandra M Swain; et al.

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):4074-82.
116.
2002

Edward A Sausville

International Society for Oncodevelopmental Biology and Medicine - XXXth Meeting.
IDrugs : the investigational drugs journal 2002;5(10):958-60.
117.
2002

Carol A Tamminga; Charles B Nemeroff; Randy D Blakely; Linda Brady; Cameron S Carter; Kenneth L Davis; Raymond Dingledine; Jack M Gorman; Dimitri E Grigoriadis; David C Henderson; et al.

Developing novel treatments for mood disorders: accelerating discovery.
Biological psychiatry 2002;52(6):589-609.
118.
2002

Suoping Zhai; Edward Sausville; William D Figg

A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma.
Biomedical chromatography : BMC 2002;16(6):379-82.
119.
2002

Annamaria Rapisarda; Badarch Uranchimeg; Dominic A Scudiero; Mike Selby; Edward A Sausville; Robert H Shoemaker; Giovanni Melillo

Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.
Cancer research 2002;62(15):4316-24.
120.
2002

Zhiyuan Xu; Zhong-Ping Chen; Areti Malapetsa; Moulay Alaoui-Jamali; Josée Bergeron; Anne Monks; Timothy G Myers; Gérard Mohr; Edward A Sausville; Dominic A Scudiero; et al.

DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program.
Anti-cancer drugs 2002;13(5):511-9.
121.
2002

Suoping Zhai; Adrian M Senderowicz; Edward A Sausville; William D Figg

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
The Annals of pharmacotherapy 2002;36(5):905-11.
122.
2002

T D Bradshaw; M-S Chua; H L Browne; V Trapani; E A Sausville; M F G Stevens

In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles.
British journal of cancer 2002;86(8):1348-54.
123.
2002

M Monga; E A Sausville

Developmental therapeutics program at the NCI: molecular target and drug discovery process.
Leukemia 2002;16(4):520-6.
124.
2002

Charles L Sawyers; Edward A Sausville

Overview: the art of cancer drug screening: molecular target versus milieu-based screens.
Current opinion in investigational drugs (London, England : 2000) 2002;3(3):478-81.
125.
2002

Vyomesh Patel; Tyler Lahusen; Terence Sy; Edward A Sausville; J Sivio Gutkind; Adrian M Senderowicz

Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest.
Cancer research 2002;62(5):1401-9.
126.
2002

Robert H Shoemaker; Dominic A Scudiero; Giovanni Melillo; Michael J Currens; Anne P Monks; Alfred A Rabow; David G Covell; Edward A Sausville

Application of high-throughput, molecular-targeted screening to anticancer drug discovery.
Current topics in medicinal chemistry 2002;2(3):229-46.
127.
2002

Zhong-ping Chen; Areti Malapetsa; Anne Monks; Timothy G Myers; Gérard Mohr; Edward A Sausville; Dominic A Scudiero; Lawrence C Panasci

Nucleotide excision repair protein levels vis-à-vis anticancer drug resistance in 60 human tumor cell lines.
Ai zheng = Aizheng = Chinese journal of cancer 2002;21(3):233-9.
128.
2002

Anders Wallqvist; Alfred A Rabow; Robert H Shoemaker; Edward A Sausville; David G Covell

Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology.
Molecular cancer therapeutics 2002;1(5):311-20.
129.
2002

Seok Hee Park; Sae Ra Lee; Byung Chul Kim; Eun Ah Cho; Sejal P Patel; Hee-Bum Kang; Edward A Sausville; Osamu Nakanishi; Jane B Trepel; Byoung Ick Lee; et al.

Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells.
The Journal of biological chemistry 2002;277(7):5168-74.
130.
2002

Alfred A Rabow; Robert H Shoemaker; Edward A Sausville; David G Covell

Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities.
Journal of medicinal chemistry 2002;45(4):818-40.
131.
2002

Paul Thambi; Edward A Sausville

STI571 (imatinib mesylate): the tale of a targeted therapy.
Anti-cancer drugs 2002;13(2):111-4.
132.
2002

Tracey D Bradshaw; Michael C Bibby; John A Double; Iduna Fichtner; Patricia A Cooper; Michael C Alley; Susan Donohue; Sherman F Stinson; Joseph E Tomaszewjski; Edward A Sausville; et al.

Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.
Molecular cancer therapeutics 2002;1(4):239-46.
133.
2002

Benjamin M F Mow; Joya Chandra; Phyllis A Svingen; Christopher G Hallgren; Ellen Weisberg; Timothy J Kottke; Ven L Narayanan; Mark R Litzow; James D Griffin; Edward A Sausville; et al.

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
Blood 2002;99(2):664-71.
134.
2002

Surendra N Pandeya; Perumal Yogeeswari; Edward A Sausville; Anthony B Mauger; Ven L Narayanan

Synthesis and antitumour evaluation of 4-bromophenyl semicarbazones.
Arzneimittel-Forschung 2002;52(2):103-8.
135.
2002

Andrea I Loaiza-Pérez; Valentina Trapani; Curtis Hose; Sheo S Singh; Jane B Trepel; Malcolm F G Stevens; Tracey D Bradshaw; Edward A Sausville

Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole.
Molecular pharmacology 2002;61(1):13-9.
136.
2002

Edward A Sausville

Complexities in the development of cyclin-dependent kinase inhibitor drugs.
Trends in molecular medicine 2002;8(4 Suppl):S32-7.
137.
2001

K K Roy; E A Sausville

Early development of cyclin dependent kinase modulators.
Current pharmaceutical design 2001;7(16):1669-87.
138.
2001

F Searle; S Gac-Breton; R Keane; S Dimitrijevic; S Brocchini; E A Sausville; R Duncan

N-(2-hydroxypropyl)methacrylamide copolymer-6-(3-aminopropyl)-ellipticine conjugates. Synthesis, in vitro, and preliminary in vivo evaluation.
Bioconjugate chemistry 2001;12(5):711-8.
139.
2001

E W Woo; R Messmann; E A Sausville; W D Figg

Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications 2001;759(2):247-57.
140.
2001

E A Sausville

Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Münster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2155-8.
141.
2001

E A Sausville

Scientific summation and future goals.
Journal of controlled release : official journal of the Controlled Release Society 2001;74(1-3):1-6.
142.
2001

J C Byrd; C Shinn; C R Willis; I W Flinn; T Lehman; E Sausville; D Lucas; M R Grever

UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.
Experimental hematology 2001;29(6):703-8.
143.
2001

L Dudkin; M B Dilling; P J Cheshire; F C Harwood; M Hollingshead; S G Arbuck; R Travis; E A Sausville; P J Houghton

Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1758-64.
144.
2001

J I Johnson; S Decker; D Zaharevitz; L V Rubinstein; J M Venditti; S Schepartz; S Kalyandrug; M Christian; S Arbuck; M Hollingshead; et al.

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.
British journal of cancer 2001;84(10):1424-31.
145.
2001

J B Sunwoo; Z Chen; G Dong; N Yeh; C Crowl Bancroft; E Sausville; J Adams; P Elliott; C Van Waes

Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1419-28.
146.
2001

E A Sausville; S G Arbuck; R Messmann; D Headlee; K S Bauer; R M Lush; A Murgo; W D Figg; T Lahusen; S Jaken; et al.

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2319-33.
147.
2001

B Hagenauer; A Salamon; T Thalhammer; O Kunert; E Haslinger; P Klingler; A M Senderowicz; E A Sausville; W Jäger

In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(4 Pt 1):407-14.
148.
2001

R Bai; P Verdier-Pinard; S Gangwar; C C Stessman; K J McClure; E A Sausville; G R Pettit; R B Bates; E Hamel

Dolastatin 11, a marine depsipeptide, arrests cells at cytokinesis and induces hyperpolymerization of purified actin.
Molecular pharmacology 2001;59(3):462-9.
149.
2001

L J Yu; J Matias; D A Scudiero; K M Hite; A Monks; E A Sausville; D J Waxman

P450 enzyme expression patterns in the NCI human tumor cell line panel.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(3):304-12.
150.
2001

B I Lee; S H Park; J W Kim; E A Sausville; H T Kim; O Nakanishi; J B Trepel; S J Kim

MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
Cancer research 2001;61(3):931-4.
151.
2001

J Schindler; E Sausville; R Messmann; J W Uhr; E S Vitetta

The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(2):255-8.
152.
2001

M E Kahn; A Senderowicz; E A Sausville; K E Barrett

Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(2):343-9.
153.
2001

E Sausville

11th NCI-EORTC-AACR: New therapeutic targets, signal transduction and angiogenesis.
IDrugs : the investigational drugs journal 2001;4(2):148-53.
154.
2001

L T Lam; O K Pickeral; A C Peng; A Rosenwald; E M Hurt; J M Giltnane; L M Averett; H Zhao; R E Davis; M Sathyamoorthy; et al.

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.
Genome biology 2001;2(10):RESEARCH0041.
155.
2001

S G Arbuck; J Dancey; J M Pluda; L Grochow; A J Murgo; P Ivy; J Wright; B Blaylock; L E Via; E A Sausville

New targets for cancer chemotherapy.
Cancer chemotherapy and biological response modifiers 2001;19():237-88.
156.
2001

Y A Elsayed; E A Sausville

Selected novel anticancer treatments targeting cell signaling proteins.
The oncologist 2001;6(6):517-37.
157.
2001

D L Newton; G Kaur; J S Rhim; E A Sausville; S M Rybak

RNA damage and inhibition of neoplastic endothelial cell growth: effects of human and amphibian ribonucleases.
Radiation research 2001;155(1 Pt 2):171-174.
158.
2001

E A Sausville; R H Shoemaker

Role of the National Cancer Institute in acquired immunodeficiency syndrome-related drug discovery.
Journal of the National Cancer Institute. Monographs 2001;(28):55-7.
159.
2001

E A Sausville

The challenge of pathway and environment-mediated drug resistance.
Cancer metastasis reviews 2001;20(1-2):117-22.
160.
2000

E A Sausville

Overview. Cancer drug discovery: pathway promise or covalent certainty for drug effect--quo vadis?
Current opinion in investigational drugs (London, England : 2000) 2000;1(4):511-3.
161.
2000

E A Sausville; J I Johnson

Molecules for the millennium: how will they look? New drug discovery year 2000.
British journal of cancer 2000;83(11):1401-4.
162.
2000

E A Sausville

Dragons 'round the fleece again: STI571 versus alpha1 acid glycoprotein.
Journal of the National Cancer Institute 2000;92(20):1626-7.
163.
2000

R Mandler; C Wu; E A Sausville; A J Roettinger; D J Newman; D K Ho; C R King; D Yang; M E Lippman; N F Landolfi; et al.

Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines.
Journal of the National Cancer Institute 2000;92(19):1573-81.
164.
2000

M Leost; C Schultz; A Link; Y Z Wu; J Biernat; E M Mandelkow; J A Bibb; G L Snyder; P Greengard; D W Zaharevitz; et al.

Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.
European journal of biochemistry / FEBS 2000;267(19):5983-94.
165.
2000

M S Chua; E Kashiyama; T D Bradshaw; S F Stinson; E Brantley; E A Sausville; M F Stevens

Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells.
Cancer research 2000;60(18):5196-203.
166.
2000

S H Chao; K Fujinaga; J E Marion; R Taube; E A Sausville; A M Senderowicz; B M Peterlin; D H Price

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication.
The Journal of biological chemistry 2000;275(37):28345-8.
167.
2000

V Sandor; A Senderowicz; S Mertins; D Sackett; E Sausville; M V Blagosklonny; S E Bates

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228.
British journal of cancer 2000;83(6):817-25.
168.
2000

K S Bauer; R M Lush; M A Rudek; C Shih; E Sausville; W D Figg

A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva.
Biomedical chromatography : BMC 2000;14(5):338-43.
169.
2000

C E Arris; F T Boyle; A H Calvert; N J Curtin; J A Endicott; E F Garman; A E Gibson; B T Golding; S Grant; R J Griffin; et al.

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Journal of medicinal chemistry 2000;43(15):2797-804.
170.
2000

V Sandor; A R Robbins; R Robey; T Myers; E Sausville; S E Bates; D L Sackett

FR901228 causes mitotic arrest but does not alter microtubule polymerization.
Anti-cancer drugs 2000;11(6):445-54.
171.
2000

E A Sausville; J Johnson; M Alley; D Zaharevitz; A M Senderowicz

Inhibition of CDKs as a therapeutic modality.
Annals of the New York Academy of Sciences 2000;910():207-21; discussion 221-2.
172.
2000

G Tudor; A Aguilera; D O Halverson; N D Laing; E A Sausville

Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels.
Cell death and differentiation 2000;7(6):574-86.
173.
2000

A Monks; E D Harris; A Vaigro-Wolff; C D Hose; J W Connelly; E A Sausville

UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines.
Investigational new drugs 2000;18(2):95-107.
174.
2000

E A Sausville

Use of immunotoxins in the treatment of lymphoma.
Cancer journal (Sudbury, Mass.) 2000;6(3):135-8.
175.
2000

M Kamishohara; S Kenney; R Domergue; D T Vistica; E A Sausville

Selective accumulation of the endoplasmic reticulum-Golgi intermediate compartment induced by the antitumor drug KRN5500.
Experimental cell research 2000;256(2):468-79.
176.
2000

R A Messmann; E S Vitetta; D Headlee; A M Senderowicz; W D Figg; J Schindler; D F Michiel; S Creekmore; S M Steinberg; D Kohler; et al.

A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1302-13.
177.
2000

O Keskin; I Bahar; R L Jernigan; J A Beutler; R H Shoemaker; E A Sausville; D G Covell

Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure.
Anti-cancer drug design 2000;15(2):79-98.
178.
2000

C Kunick; C Schultz; T Lemcke; D W Zaharevitz; R Gussio; R K Jalluri; E A Sausville; M Leost; L Meijer

2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity.
Bioorganic & medicinal chemistry letters 2000;10(6):567-9.
179.
2000

A M Senderowicz; E A Sausville

Preclinical and clinical development of cyclin-dependent kinase modulators.
Journal of the National Cancer Institute 2000;92(5):376-87.
180.
2000

U Scherf; D T Ross; M Waltham; L H Smith; J K Lee; L Tanabe; K W Kohn; W C Reinhold; T G Myers; D T Andrews; et al.

A gene expression database for the molecular pharmacology of cancer.
Nature genetics 2000;24(3):236-44.
181.
2000

P R Graves; L Yu; J K Schwarz; J Gales; E A Sausville; P M O'Connor; H Piwnica-Worms

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01.
The Journal of biological chemistry 2000;275(8):5600-5.
182.
2000

A E Frankel; R J Kreitman; E A Sausville

Targeted toxins.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):326-34.
183.
2000

W H Wilson; L Sorbara; W D Figg; E K Mont; E Sausville; K E Warren; F M Balis; K Bauer; M Raffeld; A M Senderowicz; et al.

Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):415-21.
184.
2000

E A Sausville

Protein kinase antagonists: interim challenges and issues.
Anti-cancer drug design 2000;15(1):1-2.
185.
2000

R Gussio; D W Zaharevitz; C F McGrath; N Pattabiraman; G E Kellogg; C Schultz; A Link; C Kunick; M Leost; L Meijer; et al.

Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition.
Anti-cancer drug design 2000;15(1):53-66.
186.
2000

C P Webb; C D Hose; S Koochekpour; M Jeffers; M Oskarsson; E Sausville; A Monks; G F Vande Woude

The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
Cancer research 2000;60(2):342-9.
187.
2000

P A Svingen; A Tefferi; T J Kottke; G Kaur; V L Narayanan; E A Sausville; S H Kaufmann

Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):237-49.
188.
1999

E A Sausville; E Feigal

Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(11):1287-91.
189.
1999

G Melillo; E A Sausville; K Cloud; T Lahusen; L Varesio; A M Senderowicz

Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes.
Cancer research 1999;59(21):5433-7.
190.
1999

E Kashiyama; I Hutchinson; M S Chua; S F Stinson; L R Phillips; G Kaur; E A Sausville; T D Bradshaw; A D Westwell; M F Stevens

Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
Journal of medicinal chemistry 1999;42(20):4172-84.
191.
1999

B Carlson; T Lahusen; S Singh; A Loaiza-Perez; P J Worland; R Pestell; C Albanese; E A Sausville; A M Senderowicz

Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.
Cancer research 1999;59(18):4634-41.
192.
1999

W Nieves-Neira; M I Rivera; G Kohlhagen; M L Hursey; P Pourquier; E A Sausville; Y Pommier

DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells.
Molecular pharmacology 1999;56(3):478-84.
193.
1999

C Schultz; A Link; M Leost; D W Zaharevitz; R Gussio; E A Sausville; L Meijer; C Kunick

Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity.
Journal of medicinal chemistry 1999;42(15):2909-19.
194.
1999

J B Schnier; G Kaur; A Kaiser; S F Stinson; E A Sausville; J Gardner; K Nishi; E M Bradbury; A M Senderowicz

Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein.
FEBS letters 1999;454(1-2):100-4.
195.
1999

M I Rivera; S F Stinson; D T Vistica; J L Jorden; S Kenney; E A Sausville

Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism.
Biochemical pharmacology 1999;57(11):1283-95.
196.
1999

D W Zaharevitz; R Gussio; M Leost; A M Senderowicz; T Lahusen; C Kunick; L Meijer; E A Sausville

Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
Cancer research 1999;59(11):2566-9.
197.
1999

J Adams; V J Palombella; E A Sausville; J Johnson; A Destree; D D Lazarus; J Maas; C S Pien; S Prakash; P J Elliott

Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Cancer research 1999;59(11):2615-22.
198.
1999

E A Sausville; D Zaharevitz; R Gussio; L Meijer; M Louarn-Leost; C Kunick; R Schultz; T Lahusen; D Headlee; S Stinson; et al.

Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target.
Pharmacology & therapeutics 1999;82(2-3):285-92.
199.
1999

M D Losiewicz; G Kaur; E A Sausville

Different early effets of tyrphostin AG957 and geldanamycins on mitogen-activated protein kinase and p120cbl phosphorylation in anti CD-3-stimulated T-lymphoblasts.
Biochemical pharmacology 1999;57(3):281-9.
200.
1999

E A Sausville

A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
Journal of the National Cancer Institute 1999;91(2):102-3.
201.
1999

A M Senderowicz; R Reid; D Headlee; T Abornathy; J Horti; R M Lush; E Reed; W D Figg; E A Sausville

A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer.
Urologia internationalis 1999;63(2):120-5.
202.
1998

L Yu; L Orlandi; P Wang; M S Orr; A M Senderowicz; E A Sausville; R Silvestrini; N Watanabe; H Piwnica-Worms; P M O'Connor

UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase.
The Journal of biological chemistry 1998;273(50):33455-64.
203.
1998

I Tamm; Y Wang; E Sausville; D A Scudiero; N Vigna; T Oltersdorf; J C Reed

IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.
Cancer research 1998;58(23):5315-20.
204.
1998

J C Byrd; C Shinn; J K Waselenko; E J Fuchs; T A Lehman; P L Nguyen; I W Flinn; L F Diehl; E Sausville; M R Grever

Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Blood 1998;92(10):3804-16.
205.
1998

V Patel; A M Senderowicz; D Pinto; T Igishi; M Raffeld; L Quintanilla-Martinez; J F Ensley; E A Sausville; J S Gutkind

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
The Journal of clinical investigation 1998;102(9):1674-81.
206.
1998

A M Senderowicz; D Headlee; S F Stinson; R M Lush; N Kalil; L Villalba; K Hill; S M Steinberg; W D Figg; A Tompkins; et al.

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):2986-99.
207.
1998

E Fuse; H Tanii; N Kurata; H Kobayashi; Y Shimada; T Tamura; Y Sasaki; Y Tanigawara; R D Lush; D Headlee; et al.

Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.
Cancer research 1998;58(15):3248-53.
208.
1998

D A Scudiero; A Monks; E A Sausville

Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.
Journal of the National Cancer Institute 1998;90(11):862.
209.
1998

F Arguello; M Alexander; J A Sterry; G Tudor; E M Smith; N T Kalavar; J F Greene; W Koss; C D Morgan; S F Stinson; et al.

Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts.
Blood 1998;91(7):2482-90.
210.
1998

B A Conley; M J Egorin; N Tait; D M Rosen; E A Sausville; G Dover; R J Fram; D A Van Echo

Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):629-34.
211.
1998

J C Byrd; K R Rai; E A Sausville; M R Grever

Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals.
Seminars in oncology 1998;25(1):65-74.
212.
1998

B W Parker; G Kaur; W Nieves-Neira; M Taimi; G Kohlhagen; T Shimizu; M D Losiewicz; Y Pommier; E A Sausville; A M Senderowicz

Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol.
Blood 1998;91(2):458-65.
213.
1998

S Kitada; M Krajewska; X Zhang; D Scudiero; J M Zapata; H G Wang; A Shabaik; G Tudor; S Krajewski; T G Myers; et al.

Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines.
The American journal of pathology 1998;152(1):51-61.
214.
1998

F Arguello; M A Alexander; J F Greene; S F Stinson; J L Jorden; E M Smith; N T Kalavar; W G Alvord; R L Klabansky; E A Sausville

Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts.
Journal of cancer research and clinical oncology 1998;124(1):19-26.
215.
1998

W Jäger; B Zembsch; P Wolschann; E Pittenauer; A M Senderowicz; E A Sausville; H H Sedlacek; J Graf; T Thalhammer

Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver.
Life sciences 1998;62(20):1861-73.
216.
1998

N Dawson; W D Figg; O W Brawley; R Bergan; M R Cooper; A Senderowicz; D Headlee; S M Steinberg; M Sutherland; N Patronas; et al.

Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):37-44.
217.
1998

A Engert; E A Sausville; E Vitetta

The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma.
Current topics in microbiology and immunology 1998;234():13-33.
218.
1998

E A Sausville; R D Lush; D Headlee; A C Smith; W D Figg; S G Arbuck; A M Senderowicz; E Fuse; H Tanii; T Kuwabara; et al.

Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models.
Cancer chemotherapy and pharmacology 1998;42 Suppl():S54-9.
219.
1998

H Takeuchi; G Ara; E A Sausville; B Teicher

Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma.
Cancer chemotherapy and pharmacology 1998;42(6):491-6.
220.
1997

E A Sausville

Correspondence re: G. Palumbo et al., the tyrphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2. Cancer Res., 57: 2434-2439, 1997.
Cancer research 1997;57(24):5610.
221.
1997

P M O'Connor; J Jackman; I Bae; T G Myers; S Fan; M Mutoh; D A Scudiero; A Monks; E A Sausville; J N Weinstein; et al.

Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.
Cancer research 1997;57(19):4285-300.
222.
1997

A Monks; D A Scudiero; G S Johnson; K D Paull; E A Sausville

The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.
Anti-cancer drug design 1997;12(7):533-41.
223.
1997

J P Grenert; W P Sullivan; P Fadden; T A Haystead; J Clark; E Mimnaugh; H Krutzsch; H J Ochel; T W Schulte; E Sausville; et al.

The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation.
The Journal of biological chemistry 1997;272(38):23843-50.
224.
1997

D Marcantonio; L C Panasci; M G Hollingshead; M C Alley; R F Camalier; E A Sausville; D J Dykes; C A Carter; L Malspeis

2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
Cancer research 1997;57(18):3895-8.
225.
1997

A M Senderowicz; E Vitetta; D Headlee; V Ghetie; J W Uhr; W D Figg; R M Lush; M Stetler-Stevenson; G Kershaw; D W Kingma; et al.

Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
Annals of internal medicine 1997;126(11):882-5.
226.
1997

J M Freije; J A Lawrence; M G Hollingshead; A De la Rosa; V Narayanan; M Grever; E A Sausville; K Paull; P S Steeg

Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines.
Nature medicine 1997;3(4):395-401.
227.
1997

M C Christian; J M Pluda; P T Ho; S G Arbuck; A J Murgo; E A Sausville

Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
Seminars in oncology 1997;24(2):219-40.
228.
1997

N A Dawson; W D Figg; M R Cooper; O Sartor; R C Bergan; A M Senderowicz; S M Steinberg; A Tompkins; B Weinberger; E A Sausville; et al.

Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(4):1470-7.
229.
1997

T G Myers; N L Anderson; M Waltham; G Li; J K Buolamwini; D A Scudiero; K D Paull; E A Sausville; J N Weinstein

A protein expression database for the molecular pharmacology of cancer.
Electrophoresis 1997;18(3-4):647-53.
230.
1997

W G Rice; J A Turpin; M Huang; D Clanton; R W Buckheit; D G Covell; A Wallqvist; N B McDonnell; R N DeGuzman; M F Summers; et al.

Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein.
Nature medicine 1997;3(3):341-5.
231.
1997

A M Burger; G Kaur; M Hollingshead; R T Fischer; K Nagashima; L Malspeis; K L Duncan; E A Sausville

Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(3):455-63.
232.
1997

M Drees; W A Dengler; T Roth; H Labonte; J Mayo; L Malspeis; M Grever; E A Sausville; H H Fiebig

Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(2):273-9.
233.
1997

J N Weinstein; T G Myers; P M O'Connor; S H Friend; A J Fornace; K W Kohn; T Fojo; S E Bates; L V Rubinstein; N L Anderson; et al.

An information-intensive approach to the molecular pharmacology of cancer.
Science (New York, N.Y.) 1997;275(5298):343-9.
234.
1996

H Sedlacek; J Czech; R Naik; G Kaur; P Worland; M Losiewicz; B Parker; B Carlson; A Smith; A Senderowicz; et al.

Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy.
International journal of oncology 1996;9(6):1143-68.
235.
1996

K L Duncan; M D Duncan; M C Alley; E A Sausville

Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells.
Biochemical pharmacology 1996;52(10):1553-60.
236.
1996

G Kaur; E A Sausville

Altered physical state of p210bcr-abl in tyrphostin AG957-treated K562 cells.
Anti-cancer drugs 1996;7(8):815-24.
237.
1996

R Baluna; E A Sausville; M J Stone; M A Stetler-Stevenson; J W Uhr; E S Vitetta

Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(10):1705-12.
238.
1996

J A Turpin; S J Terpening; C A Schaeffer; G Yu; C J Glover; R L Felsted; E A Sausville; W G Rice

Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles.
Journal of virology 1996;70(9):6180-9.
239.
1996

M J Stone; E A Sausville; J W Fay; D Headlee; R H Collins; W D Figg; M Stetler-Stevenson; V Jain; E S Jaffe; D Solomon; et al.

A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
Blood 1996;88(4):1188-97.
240.
1996

Q Wang; S Fan; A Eastman; P J Worland; E A Sausville; P M O'Connor

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
Journal of the National Cancer Institute 1996;88(14):956-65.
241.
1996

B A Carlson; M M Dubay; E A Sausville; L Brizuela; P J Worland

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Cancer research 1996;56(13):2973-8.
242.
1996

S U Yasuda; E A Sausville; J B Hutchins; T Kennedy; R L Woosley

Amiodarone-induced lymphocyte toxicity and mitochondrial function.
Journal of cardiovascular pharmacology 1996;28(1):94-100.
243.
1996

W F De Azevedo; H J Mueller-Dieckmann; U Schulze-Gahmen; P J Worland; E Sausville; S H Kim

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(7):2735-40.
244.
1996

J Viallet; E A Sausville

Involvement of signal transduction pathways in lung cancer biology.
Journal of cellular biochemistry. Supplement 1996;24():228-36.
245.
1996

Z Fathi; J W Way; M H Corjay; J Viallet; E A Sausville; J F Battey

Bombesin receptor structure and expression in human lung carcinoma cell lines.
Journal of cellular biochemistry. Supplement 1996;24():237-46.
246.
1996

E A Sausville; K L Duncan; A Senderowicz; J Plowman; P A Randazzo; R Kahn; L Malspeis; M R Grever

Antiproliferative effect in vitro and antitumor activity in vivo of brefeldin A.
The cancer journal from Scientific American 1996;2(1):52-8.
247.
1995

F M Foss; E A Sausville

Prognosis and staging of cutaneous T-cell lymphoma.
Hematology/oncology clinics of North America 1995;9(5):1011-9.
248.
1995

Q Wang; P J Worland; J L Clark; B A Carlson; E A Sausville

Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1995;6(8):927-36.
249.
1995

N A Dawson; M R Cooper; W D Figg; D J Headlee; A Thibault; R C Bergan; S M Steinberg; E A Sausville; C E Myers; O Sartor

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
Cancer 1995;76(3):453-62.
250.
1995

A M Burger; G Kaur; M C Alley; J G Supko; L Malspeis; M R Grever; E A Sausville

Tyrphostin AG17, [(3,5-Di-tert-butyl-4-hydroxybenzylidene)- malononitrile], inhibits cell growth by disrupting mitochondria.
Cancer research 1995;55(13):2794-9.
251.
1995

E A Sausville; D Headlee; M Stetler-Stevenson; E S Jaffe; D Solomon; W D Figg; J Herdt; W C Kopp; H Rager; S M Steinberg

Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.
Blood 1995;85(12):3457-65.
252.
1995

N Takahashi; E A Sausville; T R Breitman

N-(4-hydroxyphenyl)retinamide (Fenretinide) in combination with retinoic acid enhances differentiation and retinoylation of proteins.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(6):637-42.
253.
1995

A M Senderowicz; G Kaur; E Sainz; C Laing; W D Inman; J Rodríguez; P Crews; L Malspeis; M R Grever; E A Sausville

Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton.
Journal of the National Cancer Institute 1995;87(1):46-51.
254.
1994

M Kuchnio; E A Sausville; E S Jaffe; T Greiner; F M Foss; J McClanahan; P Fukushima; M A Stetler-Stevenson

Flow cytometric detection of neoplastic T cells in patients with mycosis fungoides based on levels of T-cell receptor expression.
American journal of clinical pathology 1994;102(6):856-60.
255.
1994

M J McCarty; S J Vukelja; E A Sausville; J J Perry; W D James; E S Jaffe; R B Weiss

Lymphomatoid papulosis associated with Ki-1-positive anaplastic large cell lymphoma. A report of two cases and a review of the literature.
Cancer 1994;74(11):3051-8.
256.
1994

R Cohen; E S Jaffe; M A Stetler-Stevenson; E A Sausville; E C DeNigris; T Woodworth; F M Foss

Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB486 interleukin-2).
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(3):229-33.
257.
1994

M D Losiewicz; B A Carlson; G Kaur; E A Sausville; P J Worland

Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.
Biochemical and biophysical research communications 1994;201(2):589-95.
258.
1994

C M Seynaeve; M G Kazanietz; P M Blumberg; E A Sausville; P J Worland

Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue.
Molecular pharmacology 1994;45(6):1207-14.
259.
1994

M R Bubb; A M Senderowicz; E A Sausville; K L Duncan; E D Korn

Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin.
The Journal of biological chemistry 1994;269(21):14869-71.
260.
1994

G Kaur; A Gazit; A Levitzki; E Stowe; D A Cooney; E A Sausville

Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
Anti-cancer drugs 1994;5(2):213-22.
261.
1994

F M Foss; Y Koc; M A Stetler-Stevenson; D T Nguyen; M C O'Brien; R Turner; E A Sausville

Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sézary syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(2):326-35.
262.
1993

P J Worland; G Kaur; M Stetler-Stevenson; S Sebers; O Sartor; E A Sausville

Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity.
Biochemical pharmacology 1993;46(10):1831-40.
263.
1993

M Danilenko; P Worland; B Carlson; E A Sausville; Y Sharoni

Selective effects of mastoparan analogs: separation of G-protein-directed and membrane-perturbing activities.
Biochemical and biophysical research communications 1993;196(3):1296-302.
264.
1993

S J Graham; R W Sharpe; S M Steinberg; J D Cotelingam; E A Sausville; F M Foss

Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the Sézary syndrome.
Cancer 1993;72(3):726-34.
265.
1993

D Dobrzanski; Y Sharoni; E Wada; J Battey; E Sausville

Neuromedin-B receptor transfected BALB/3T3 cells: signal transduction and effects of ectopic receptor expression on cell growth.
Regulatory peptides 1993;45(3):341-52.
266.
1993

C M Seynaeve; M Stetler-Stevenson; S Sebers; G Kaur; E A Sausville; P J Worland

Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells.
Cancer research 1993;53(9):2081-6.
267.
1993

Z Fathi; M H Corjay; H Shapira; E Wada; R Benya; R Jensen; J Viallet; E A Sausville; J F Battey

BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells.
The Journal of biological chemistry 1993;268(8):5979-84.
268.
1993

J Laborda; E A Sausville; T Hoffman; V Notario

dlk, a putative mammalian homeotic gene differentially expressed in small cell lung carcinoma and neuroendocrine tumor cell line.
The Journal of biological chemistry 1993;268(6):3817-20.
269.
1992

G Kaur; M Stetler-Stevenson; S Sebers; P Worland; H Sedlacek; C Myers; J Czech; R Naik; E Sausville

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275.
Journal of the National Cancer Institute 1992;84(22):1736-40.
270.
1992

E A Sausville

T-cell leukemia-lymphoma and mycosis fungoides.
Current opinion in oncology 1992;4(5):829-39.
271.
1992

J W Lynch; I Linoilla; E A Sausville; S M Steinberg; B C Ghosh; D T Nguyen; G P Schechter; A B Fischmann; D C Ihde; J L Stocker

Prognostic implications of evaluation for lymph node involvement by T-cell antigen receptor gene rearrangement in mycosis fungoides.
Blood 1992;79(12):3293-9.
272.
1992

G Kaur; J Viallet; J Laborda; O Blair; A F Gazdar; J D Minna; E A Sausville

Growth inhibition by cholera toxin of human lung carcinoma cell lines: correlation with GM1 ganglioside expression.
Cancer research 1992;52(12):3340-6.
273.
1991

M H Corjay; D J Dobrzanski; J M Way; J Viallet; H Shapira; P Worland; E A Sausville; J F Battey

Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells.
The Journal of biological chemistry 1991;266(28):18771-9.
274.
1991

D M Atienza; R J Vigersky; E E Lack; M Carriaga; E J Rusnock; E Tsou; F Cerrone; J G Kattah; E A Sausville

Prolactin-producing pituitary carcinoma with pulmonary metastases.
Cancer 1991;68(7):1605-10.
275.
1991

J L Mulshine; J A Carrasquillo; J N Weinstein; A M Keenan; J C Reynolds; J Herdt; P A Bunn; E Sausville; J Eddy; J D Cotelingam

Direct intralymphatic injection of radiolabeled 111In-T101 in patients with cutaneous T-cell lymphoma.
Cancer research 1991;51(2):688-95.
276.
1990

J Viallet; Y Sharoni; H Frucht; R T Jensen; J D Minna; E A Sausville

Cholera toxin inhibits signal transduction by several mitogens and the in vitro growth of human small-cell lung cancer.
The Journal of clinical investigation 1990;86(6):1904-12.
277.
1990

K G Bhatia; B W Cherney; K Huppi; I T Magrath; J Cossman; E Sausville; F Barriga; B Johnson; B Gause; G Bonney

A deletion linked to a poly(ADP-ribose) polymerase gene on chromosome 13q33-qter occurs frequently in the normal black population as well as in multiple tumor DNA.
Cancer research 1990;50(17):5406-13.
278.
1990

Y Sharoni; J Viallet; J B Trepel; E A Sausville

Effect of guanine and adenine nucleotides on bombesin-stimulated phospholipase C activity in membranes from Swiss 3T3 and small cell lung carcinoma cells.
Cancer research 1990;50(17):5257-62.
279.
1990

E A Sausville; J B Trepel; J D Moyer

Inhibitors of bombesin-stimulated intracellular signals: interruption of an autocrine pathway as a therapeutic strategy in small cell lung carcinoma.
Progress in clinical and biological research 1990;354A():193-207.
280.
1990

E C Kohn; R G Steis; E A Sausville; S R Veach; J L Stocker; R Phelps; S Franco; D L Longo; P A Bunn; D C Ihde

Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(1):155-60.
281.
1989

A Rosolen; M Nakanishi; D G Poplack; D Cole; R Quinones; G Reaman; J B Trepel; J D Cotelingam; E A Sausville; G E Marti

Expression of interleukin-2 receptor beta subunit in hematopoietic malignancies.
Blood 1989;73(7):1968-72.
282.
1989

J L Mulshine; R B Natale; I Avis; A M Treston; P G Kasprzyk; Y Nakanishi; E A Sausville; J B Trepel; F Cuttitta

Autocrine growth factors and lung cancer.
Cancer treatment and research 1989;45():107-22.
283.
1988

J B Trepel; J D Moyer; F Cuttitta; H Frucht; D H Coy; R B Natale; J L Mulshine; R T Jensen; E A Sausville

A novel bombesin receptor antagonist inhibits autocrine signals in a small cell lung carcinoma cell line.
Biochemical and biophysical research communications 1988;156(3):1383-9.
284.
1988

J B Trepel; J D Moyer; R Heikkila; E A Sausville

Modulation of bombesin-induced phosphatidylinositol hydrolysis in a small-cell lung-cancer cell line.
The Biochemical journal 1988;255(2):403-10.
285.
1988

J De Greve; J Battey; J Fedorko; M Birrer; G Evan; F Kaye; E Sausville; J Minna

The human L-myc gene encodes multiple nuclear phosphoproteins from alternatively processed mRNAs.
Molecular and cellular biology 1988;8(10):4381-8.
286.
1988

E A Sausville; J L Eddy; R W Makuch; A B Fischmann; G P Schechter; M Matthews; E Glatstein; D C Ihde; F Kaye; S R Veach

Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
Annals of internal medicine 1988;109(5):372-82.
287.
1988

S Markowitz; G Krystal; A M Lebacq-Verheyden; J Way; E A Sausville; J Battey

Transcriptional activation and DNase I hypersensitive sites are associated with selective expression of the gastrin-releasing peptide gene.
The Journal of clinical investigation 1988;82(3):808-15.
288.
1988

G Krystal; M Birrer; J Way; M Nau; E Sausville; C Thompson; J Minna; J Battey

Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancer.
Molecular and cellular biology 1988;8(8):3373-81.
289.
1988

M J Birrer; S Segal; J S DeGreve; F Kaye; E A Sausville; J D Minna

L-myc cooperates with ras to transform primary rat embryo fibroblasts.
Molecular and cellular biology 1988;8(6):2668-73.
290.
1988

O R Colamonici; R Quinones; A Rosolen; J B Trepel; E Sausville; J C Phares; R Gress; D Poplack; J Weber; G P Schechter

The beta subunit of the interleukin-2 receptor mediates interleukin-2 induction of anti-CD3 redirected cytotoxic capability in large granular lymphocytes.
Blood 1988;71(3):825-8.
291.
1988

J D Minna; F Cuttitta; J F Battey; J L Mulshine; I Linnoila; A F Gazdar; J Trepel; E A Sausville

Gastrin-releasing peptide and other autocrine growth factors in lung cancer: pathogenetic and treatment implications.
Important advances in oncology 1988;():55-64.
292.
1988

E A Sausville; J D Moyer; R Heikkila; L M Neckers; J B Trepel

A correlation of bombesin-responsiveness with myc-family gene expression in small cell lung carcinoma cell lines.
Annals of the New York Academy of Sciences 1988;547():310-21.
293.
1988

F Kaye; J Battey; M Nau; B Brooks; E Seifter; J De Greve; M Birrer; E Sausville; J Minna

Structure and expression of the human L-myc gene reveal a complex pattern of alternative mRNA processing.
Molecular and cellular biology 1988;8(1):186-95.
294.
1987

R Heikkila; J B Trepel; F Cuttitta; L M Neckers; E A Sausville

Bombesin-related peptides induce calcium mobilization in a subset of human small cell lung cancer cell lines.
The Journal of biological chemistry 1987;262(34):16456-60.
295.
1987

A Veillette; F M Foss; E A Sausville; J B Bolen; N Rosen

Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines.
Oncogene research 1987;1(4):357-74.
296.
1987

J B Trepel; O R Colamonici; K Kelly; G Schwab; R A Watt; E A Sausville; E S Jaffe; L M Neckers

Transcriptional inactivation of c-myc and the transferrin receptor in dibutyryl cyclic AMP-treated HL-60 cells.
Molecular and cellular biology 1987;7(7):2644-8.
297.
1987

F J Kaye; O W McBride; J F Battey; A F Gazdar; E A Sausville

Human creatine kinase-B complementary DNA. Nucleotide sequence, gene expression in lung cancer, and chromosomal assignment to two distinct loci.
The Journal of clinical investigation 1987;79(5):1412-20.
298.
1987

G P Schechter; E A Sausville; A B Fischmann; F Soehnlen; J Eddy; M Matthews; A Gazdar; J Guccion; D Munson; R Makuch

Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma.
Blood 1987;69(3):841-9.
299.
1987

E Dmitrovsky; M J Matthews; P A Bunn; G P Schechter; R W Makuch; C F Winkler; J Eddy; E A Sausville; D C Ihde

Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(2):208-15.
300.
1986

C F Winkler; E A Sausville; D C Ihde; A B Fischmann; G P Schechter; P P Kumar; J R Nibhanupdi; J D Minna; R W Makuch; J L Eddy

Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(7):1094-100.
301.
1986

E J Seifter; E A Sausville; J Battey

Comparison of amplified and unamplified c-myc gene structure and expression in human small cell lung carcinoma cell lines.
Cancer research 1986;46(4 Pt 2):2050-5.
302.
1986

E A Sausville; A M Lebacq-Verheyden; E R Spindel; F Cuttitta; A F Gazdar; J F Battey

Expression of the gastrin-releasing peptide gene in human small cell lung cancer. Evidence for alternative processing resulting in three distinct mRNAs.
The Journal of biological chemistry 1986;261(5):2451-7.
303.
1986

M M Nau; B J Brooks; D N Carney; A F Gazdar; J F Battey; E A Sausville; J D Minna

Human small-cell lung cancers show amplification and expression of the N-myc gene.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(4):1092-6.
304.
1986

J D Minna; J F Battey; M Birrer; B J Brooks; F Cuttitta; J DeGreve; A F Gazdar; B E Johnson; M M Nau; E A Sausville

Chromosomal deletion, gene amplification, alternative processing, and autocrine growth factor production in the pathogenesis of human lung cancer.
Princess Takamatsu symposia 1986;17():109-22.
305.
1985

M M Nau; B J Brooks; J Battey; E Sausville; A F Gazdar; I R Kirsch; O W McBride; V Bertness; G F Hollis; J D Minna

L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer.
Nature 1985;318(6041):69-73.
306.
1985

E A Sausville; G F Worsham; M J Matthews; R W Makuch; A B Fischmann; G P Schechter; A F Gazdar; P A Bunn

Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system.
Human pathology 1985;16(11):1098-109.
307.
1985

E Sausville; D Carney; J Battey

The human vasopressin gene is linked to the oxytocin gene and is selectively expressed in a cultured lung cancer cell line.
The Journal of biological chemistry 1985;260(18):10236-41.
308.
1978

E A Sausville; S B Horwitz

Inhibition of SV40 DNA synthesis by camptothecin and neocarzinostatin.
Molecular pharmacology 1978;14(6):1156-66.
309.
1978

E A Sausville; J Peisach; S B Horwitz

Effect of chelating agents and metal ions on the degradation of DNA by bleomycin.
Biochemistry 1978;17(14):2740-6.
310.
1978

E A Sausville; R W Stein; J Peisach; S B Horwitz

Properties and products of the degradation of DNA by bleomycin and iron(II).
Biochemistry 1978;17(14):2746-54.
311.
1976

E A Sausville; J Peisach; S B Horwitz

A role for ferrous ion and oxygen in the degradation of DNA by bleomycin.
Biochemical and biophysical research communications 1976;73(3):814-22.
312.
1975

G B Villanueva; C W Batt; E Sausville; V Tortorelli; K Cubelli; W Brunner

Changes in the exposure of tryptophyl and tyrosyl residues in thrombin due to diisopropylphosphorofluoridate and benzamidine inhibitions.
Biochemical and biophysical research communications 1975;67(1):359-65.

Edward A Sausville School of Medicine, Medicine

Edward A Sausville

312 Publications

Edward A Sausville
School of Medicine, Medicine